SEC Comment Letter 0000000000-26-005065 to Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc.
Date: May 18, 2026 · CIK: 0001840233 · Accession: 0000000000-26-005065
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295785
Letter
May 18, 2026 René Russo Chief Executive Officer Xilio Therapeutics, Inc. 828 Winter Street, Suite 300 Waltham, MA 02451 Re: Xilio Therapeutics, Inc. Registration Statement on Form S-3 Filed May 12, 2026 File No. 333-295785 Dear René Russo : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Molly Fox
Show Raw Text
May 18, 2026
René Russo
Chief Executive Officer
Xilio Therapeutics, Inc.
828 Winter Street, Suite 300
Waltham, MA 02451
Re: Xilio Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 12, 2026
File No. 333-295785
Dear René Russo :
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Molly Fox